Skye Bioscience (SKYE) Other financing activities (2018 - 2024)
Skye Bioscience (SKYE) posted quarterly Other financing activities of $85.7 million for Q1 2024, up 1421484.28% quarter-over-quarter from -$6026.0 in Q4 2023.
Skye Bioscience (SKYE) Other financing activities (2018 - 2024) Analysis & Trends
Skye Bioscience (SKYE) has reported Other financing activities for 5 consecutive years, with $85.7 million the latest figure, recorded in Q1 2024.
- In Q1 2024, Other financing activities changed N/A year-over-year to $85.7 million; the TTM figure through Mar 2024 stood at $85.7 million (up 4354579.77% YoY), while the FY2025 annual figure was $29571.0, up 426.36% from the prior year.
- Other financing activities climbed to $85.7 million in Q1 2024 per SKYE's latest filing, from -$6026.0 in the prior quarter.
- Across five years, Other financing activities topped out at $85.7 million in Q1 2024 and bottomed at -$7017.0 in Q2 2021.
- Historically, Other financing activities has averaged $11.6 million across 4 years, with a median of $3996.5 in 2022.
- Annual changes were most pronounced in 2022 — Other financing activities sank 83.33% — and 2023, when it jumped 406.35%.
- Skye Bioscience's Other financing activities stood at $7.0 million in 2021, then sank by 100.03% to -$1967.0 in 2022, then sank by 206.35% to -$6026.0 in 2023, then surged by 1421484.28% to $85.7 million in 2024.
- Business Quant data shows SKYE's Other financing activities at $85.7 million in Q1 2024, -$6026.0 in Q4 2023, and $6026.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Skye Bioscience | 11.17 Mn | 11.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 85.65 Mn |
| Mar 31, 2024 | 85.65 Mn |
| Dec 31, 2023 | -6,026.00 |
| Dec 31, 2023 | -6,026.00 |
| Sep 30, 2023 | 6,026.00 |
| Sep 30, 2023 | 6,026.00 |
| Sep 30, 2022 | -1,967.00 |
| Sep 30, 2022 | -1,967.00 |
| Mar 31, 2022 | 1,967.00 |
| Mar 31, 2022 | 1,967.00 |
| Dec 31, 2021 | 7.00 Mn |
| Dec 31, 2021 | 7.00 Mn |
| Jun 30, 2021 | -7,017.00 |
| Jun 30, 2021 | -7,017.00 |
| Mar 31, 2021 | 11,800.00 |
| Mar 31, 2021 | 11,800.00 |
| Mar 31, 2018 | 98,700.00 |
| Mar 31, 2018 | 98,700.00 |